Trinity Biotech

Trinity Biotech Shares Outstanding

The The number of shares of Trinity Biotech (TRIB) as of Nov 22, 2026 is 353.21 M. In the previous year, The number of shares was 353.21 M — a change of 0.00% (lower).

Shares Outstanding

353.21 M

YoY

0.00%

Last updated:

In 2025, Trinity Biotech had 353.21 M outstanding stocks, a 0.00% change from the 353.21 M stocks in the previous year.

The Trinity Biotech Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2019
353.21 M USD
Jan 1, 2020
353.21 M USD
Jan 1, 2021
353.21 M USD
Jan 1, 2022
353.21 M USD
Jan 1, 2023
353.21 M USD
Jan 1, 2024
353.21 M USD
Jan 1, 2025
353.21 M USD
Jan 1, 2026 (e)
374.21 USD
The Trinity Biotech Shares Outstanding history
YEARShares OutstandingYoY
est374.21-100.00%
353.21 M0.00%
353.21 M0.00%
353.21 M0.00%
353.21 M0.00%
353.21 M0.00%
353.21 M0.00%
353.21 M0.00%
353.21 M0.00%
353.21 M0.00%
353.21 M0.00%
353.21 M0.00%
353.21 M+1.46 B%
24.22+7.34%
22.56+1.84%
22.15-0.21%
22.20+5.27%
21.09+1.13%
20.85+9.53%
19.04+0.34%
18.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Number of shares

Trinity Biotech shares outstanding

The number of shares of Trinity Biotech was 374.21 M in 2025. This indicates how many shares Trinity Biotech is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
25.47 M Stocks
Jan 1, 2020
26.66 M Stocks
Jan 1, 2021
175,200.00 Stocks
Jan 1, 2022
254,100.00 Stocks
Jan 1, 2023
8.87 M Stocks
Jan 1, 2024
472,500.00 Stocks
Jan 1, 2025
374.21 M Stocks
Jan 1, 2026 (e)
374.21 M Stocks

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating Trinity Biotech's Shares Outstanding

Trinity Biotech's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Trinity Biotech’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Trinity Biotech’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Trinity Biotech’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Trinity Biotech stock

The number of shares of Trinity Biotech is 353.21 M in 2025.

The number of shares of Trinity Biotech changed from 353.21 M to 353.21 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Trinity Biotech

All Key Metrics — Trinity Biotech